A flat rate, and it says which doses the flat rate covers
On a dose-tiered plan the monthly bill rises at exactly the point the medication starts working. Precision Telemed does not do that. It publishes one figure per drug that holds every month, and prints the dose range that figure covers next to it.
That second half is the unusual part. Plenty of sellers advertise a flat rate; far fewer tell you which doses it is flat across. Here the semaglutide programme names its range and the tirzepatide programme names its own, so a reader can tell before buying whether the dose they expect to reach is inside the price.
The tirzepatide programme opens on a lower first month and states the ongoing rate in the same sentence. This roster records the ongoing rate, because that is the figure that describes a year, and records the first month separately as what it is.
The maintenance plans are a different product, not a discount
Each drug also has a maintenance lane priced below the full programme, and each is restricted to the lowest dose. The seller says so in plain words on both pages.
That restriction is doing all the work. A maintenance plan is for somebody who has already reached their weight and is holding it, not for somebody starting treatment and titrating upward. A reader who sorts a comparison table by price will land on the maintenance figure first, and it is not the figure that describes their first year.
The qualifier printed beside each figure on this page carries the dose restriction. On this provider, read it before anything else.
The sentence the FDA has publicly called false
A disclaimer on both product pages says the medications are made in state-board-licensed sterile compounding pharmacies, or in FDA-licensed outsourcing facilities. That last phrase is not a description of anything. The agency does not approve or license any facility, and its own guidance to telehealth companies names that exact claim as false or misleading.
This is not an accusation of bad medicine and it is not an enforcement action. It is a sentence about regulatory status that is not true as written, on a page whose entire purpose is to establish trust about regulatory status.
What a reader should take from it is narrow and useful. Read this company's regulatory language literally rather than generously, and do not treat a reference to the agency on a compounded product page as approval of anything. The company has no warning letter in the agency's published record.
No membership, stated twice, and scoped to the right line
The semaglutide page says no membership fee. The tirzepatide page says no subscription required and everything included, no hidden fees. Twenty-six of the sixty-five sellers here state something equivalent, and this roster only records a membership as absent when the seller says so.
The scoping matters here more than usual, because the same site sells several unrelated wellness products. A fee statement made about a storefront is not a fee statement about a GLP-1 plan. The wording checked here sits on the two GLP-1 product pages themselves.
The practical consequence is that the plan figure is closer to a bill than a headline figure from a seller who charges a separate monthly membership underneath the medication price.
What is named and what is described
Precision Telemed names individual clinicians with credentials and a federal provider number, which is checkable in a national registry. Five sellers on this roster publish a prescriber's number that way, and this is one of them. The numbers are the seller's own published claims and were not looked up here.
It also states plainly on every page that the platform and the medical practice are two entities, and names both. That is a structural disclosure most of this field leaves implicit.
The pharmacy is described by licensing class and never named. A licensing category tells you what kind of pharmacy is involved. It does not let you look up the one preparing your medication, which is the thing a cautious reader actually wants — and on this row it is the disclosure that would have made the regulatory sentence above easier to check.
Precision Telemed's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $149.99/moPer month, flat rate every month, cancel anytime. The plan states "All doses included (0.25 mg – 2.5 mg)" and "Everything included, no hidden fees". A three-month supply is also published as a single payment covering three months. | September 2026source |
| Semaglutide (compounded) | $139.99/moPer month, flat rate every month, but dose-restricted in the seller's own words: "Lowest dose only (0.25 mg) to maintain your current weight". It is not a cheaper version of the full programme. | September 2026source |
| Tirzepatide (compounded) | $249.99/moThe ongoing rate, per month: "$199 /first month then $249.99/month, cancel anytime", with "All Compounded Tirzepatide Doses Included (2 mg – 15 mg)". The lower first month is recorded separately. | September 2026source |
| Tirzepatide (compounded) | $179.99/moPer month, flat rate every month, cancel anytime, and dose-restricted: "Lowest dose only (2 mg)". A three-month supply is also published as one payment covering three months. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 65 providers reviewed here are paid partners today; the other 61 are not. See how this works.
See Precision Telemed's current price →Good fit if
- Readers who want one figure that holds every month across a stated dose range, rather than a price that climbs as the dose does.
- Buyers who want the prescribing clinicians named with a number they can check in a national registry.
- People who want a written statement that no membership and no subscription apply, on the product page rather than in marketing copy.
- Readers who need nationwide availability stated on the site rather than discovered at intake.
Look elsewhere if
- Anyone who takes a seller's regulatory wording as evidence. This one describes its pharmacies in terms the agency has publicly called false or misleading.
- Readers who require the compounding pharmacy to be named. This site goes as far as a licensing class.
- Buyers drawn to the lowest figure on the row, which is a maintenance plan restricted to the starting dose.
- People comparing entry prices, since the tirzepatide programme opens on a lower first month than it continues at.
How this review was verified
- Read both product pages in a browser and audited every dollar element for computed opacity, visibility and a real laid-out rectangle before recording a figure.
- Recorded the ongoing tirzepatide rate rather than its first month, and recorded the first month separately as an introductory offer so the two cannot be confused.
- Carried the dose restriction into the qualifier on both maintenance lanes, because a figure recorded without it would be describing a different product.
- Left the three-month prepaid supplies out of the price rows on purpose. They are a single payment covering three months, not a monthly rate, and the roster keeps prepaid totals out of a field a page treats as monthly.
- Quoted the seller's own pharmacy-status disclaimer and checked it against the agency's published guidance to telehealth companies, which names that claim as false or misleading. The quotation is the seller's; the correction is the agency's.
- Confirmed the operating company, the medical practice it works with, the printed address and the governing-law clause on the terms page.
- Searched the agency's published warning-letter record for the operating company and the named medical practice, 2017 to 2026, and found nothing. That search covers warning letters only; untitled letters are published separately and were not searched.